Julie Lang

Dr. Julie Lang

Surgical Oncology
6780 Mayfield Road, 
Mayfield Hts, OH 
On Staff At
Clinical Trials:Currently Recruiting for 3 Trials
31 Years of Experience
6780 Mayfield Road, 
Mayfield Hts, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Julie Lang is a Surgical Oncologist in Mayfield Hts, Ohio. Dr. Lang has been practicing medicine for over 31 years and is rated as an Experienced provider by MediFind in Mastectomy. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Intraductal Papilloma, Tissue Biopsy, and Lymphadenectomy.

Her clinical research consists of co-authoring 90 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of North Carolina, 1995.0
Residency
UCSF Department of Surgery
Specialties
Surgical Oncology
Licenses
Surgery in CA
Board Certifications
American Board Of Surgery, 2006
Fellowships
MD Anderson Cancer Center
Hospital Affiliations
Cleveland Clinic
Hillcrest Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Hillcrest Hospital
6780 Mayfield Road, Mayfield Hts, OH 44124

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Core Biopsies of Breast Tumor Tissue Repository
Core Biopsies of Breast Tumor Tissue Repository
Enrollment Status: Recruiting
Publish Date: November 13, 2025
Intervention Type: Other
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Enrollment Status: Recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Standard Therapy, AMG 386 +/- Trastuzumab, AMG 479 (Ganitumab)+Metformin, MK-2206 +/- Trastuzumab, AMG 386+Trastuzumab, T-DM1+Pertuzumab, Pertuzumab+Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 Cycle, Talazoparib+Irinotecan, Patritumab+Trastuzumab, Pembrolizumab - 8 Cycle, SGN-LIV1A, Durvalumab+Olaparib, SD-101+Pembrolizumab, Tucatinib+Trastuzumab and Pertuzumab, Cemiplimab, Cemiplimab+REGN3767, Trilaciclib +/- Trastuzumab+Pertuzumab, SYD985 ([vic-]Trastuzumab Duocarmazine), Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042)+Carboplatin +/- Trastuzumab, Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042) +/- Trastuzumab
Study Phase: Phase 2
I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients
I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients
Enrollment Status: Recruiting
Publish Date: March 19, 2024
Intervention Type: Drug, Biological
Study Drugs: Remdesivir, Cenicriviroc, Icatibant, Pulmozyme, IC14, Celecoxib, Narsoplimab
Study Phase: Phase 2
Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women
Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Other, Drug
Study Drug: Metformin Hydrochloride
Study Phase: Phase 3
Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology
Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Procedure, Other
Study Phase: Not Applicable
A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ
A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Conjugated Estrogens/Bazedoxifene
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Enrollment Status: Withdrawn
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Diagnostic test
Phase 1/2 Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases
Phase 1/2 Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

89 Total Publications

Novel investigational modalities for clinical breast imaging: A narrative review.
Novel investigational modalities for clinical breast imaging: A narrative review.
Journal: Clinical imaging
Published: April 08, 2025
Similar Doctors
Advanced in Mastectomy
Dr. Robert R. Shenk
Surgical Oncology | General Surgery
Advanced in Mastectomy
Dr. Robert R. Shenk
Surgical Oncology | General Surgery
11100 Euclid Ave, 
Cleveland, OH 
 (8.9 miles away)
216-844-7874
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Shenk is a Surgical Oncologist and a General Surgeon in Cleveland, Ohio. Dr. Shenk is rated as a Distinguished provider by MediFind in Mastectomy. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Mastectomy, and Lymphadenectomy. Dr. Shenk is currently accepting new patients.

Advanced in Mastectomy
Dr. Amanda L. Amin
General Surgery | Surgical Oncology
Advanced in Mastectomy
Dr. Amanda L. Amin
General Surgery | Surgical Oncology

University Hospitals Medical Group Inc

11100 Euclid Ave, 
Cleveland, OH 
 (8.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amanda Amin is a General Surgeon and a Surgical Oncologist in Cleveland, Ohio. Dr. Amin is rated as a Distinguished provider by MediFind in Mastectomy. Her top areas of expertise are Intraductal Papilloma, Breast Cancer, Inflammatory Breast Cancer, Mastectomy, and Parathyroidectomy. Dr. Amin is currently accepting new patients.

Advanced in Mastectomy
Dr. Ashley B. Simpson
General Surgery | Surgical Oncology
Advanced in Mastectomy
Dr. Ashley B. Simpson
General Surgery | Surgical Oncology

University Hospitals Medical Group Inc

11100 Euclid Ave, 
Cleveland, OH 
 (8.9 miles away)
216-844-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ashley Simpson is a General Surgeon and a Surgical Oncologist in Cleveland, Ohio. Dr. Simpson is rated as a Distinguished provider by MediFind in Mastectomy. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Mastectomy. Dr. Simpson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lang's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile